A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer
The purpose of this phase 2, multiple-cohort, randomized, open-label, international study of talazoparib (a poly (ADP-ribose) polymerase (PARP) inhibitor) is to compare the efficacy and safety of talazoparib monotherapy and talazoparib plus temozolomide in women with relapsed ovarian, fallopian tube, and peritoneal cancer.
Ovarian Cancer
DRUG: Talazoparib|DRUG: Temozolomide
Determine Objective Response Rate (ORR), Anticipated in about 44 months following first patient enrolled
Progression-free survival (PFS), Anticipated in about 44 months following first patient enrolled|PFS at 24 weeks, Anticipated in about 44 months following first patient enrolled|Gynecologic Cancer Intergroup (GCIG) CA125 response rate, Anticipated in about 44 months following first patient enrolled|Clinical benefit rate at 24 weeks, Anticipated in about 44 months following first patient enrolled|Duration of response (DOR), Anticipated in about 44 months following first patient enrolled|Time to response, Anticipated in about 44 months following first patient enrolled|Overall survival, Anticipated in about 44 months following first patient enrolled|Safety as assessed by percentage of patients with any Adverse Event (AE), AE leading to Study Drug Discontinuation, AE leading to death, SAE, AE related to study drug, SAE related to study drug., Anticipated in about 44 months following first patient enrolled|Pharmacokinetics of talazoparib as assessed by trough plasma concentrations, Anticipated in about 44 months following first patient enrolled
The purpose of this phase 2, multiple-cohort, randomized, open-label, international study of talazoparib (a poly (ADP-ribose) polymerase (PARP) inhibitor) is to compare the efficacy and safety of talazoparib monotherapy and talazoparib plus temozolomide in women with relapsed ovarian, fallopian tube, and peritoneal cancer.